QUÉBEC CITY, May 22,
2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,
TSX: AEZ) (the "Company") today announced that a poster will
be presented on the design of its current ZoptEC
(Zoptarelin doxorubicin in Endometrial Cancer)
Phase 3 trial in women with advanced, recurrent or metastatic
endometrial cancer. The poster will be presented by lead
investigator, David S. Miller MD, of
the University of Texas Southwestern Medical
Center in Dallas, during the 50th Annual Meeting
of the American Society of Clinical Oncology (ASCO), to be held
May 30-June 4, 2014 in Chicago. There are currently over 100 sites in
operation and over 150 patients have been recruited for this ZoptEC
Phase 3 trial.
Abstract TPS5630: |
"ZoptEC: Phase 3 study of
zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated
endometrial cancer (Study AEZS-108-050)", David S. Miller, Hani
Gabra, Guenter Emons, D. Scott McMeekin, Amit M. Oza, Sarah Madhu
Temkin, Ignace Vergote. |
|
|
Presenter: |
Dr. David S. Miller |
Poster Session: |
Gynecologic Cancer |
Date & Time: |
Saturday, May 31, 2014, 8:00 am -
11:45 am (Central time) |
Venue: |
S Hall A2, McCormick Place,
Chicago |
About Zoptarelin Doxorubicin
Zoptarelin doxorubicin represents a new targeting concept in
oncology using a hybrid molecule composed of a synthetic peptide
carrier and a well-known chemotherapy agent, doxorubicin.
Zoptarelin doxorubicin is the first intravenous drug in advanced
clinical development that directs the chemotherapy agent
specifically to LHRH-receptor expressing tumors, resulting in a
more targeted treatment with less damage to healthy tissue. The
Company is currently conducting a Phase 3 trial in endometrial
cancer under a Special Protocol Assessment, while zoptarelin
doxorubicin is also in an investigator-initiated Phase 2 trial in
prostate cancer. Aeterna Zentaris owns the worldwide rights to this
compound.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds at
various stages of development. For more information, visit
www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.